Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA.
Cancer Res. 2010 Jun 15;70(12):5046-53. doi: 10.1158/0008-5472.CAN-09-3979. Epub 2010 May 18.
The antiapoptotic protein FLIP(S) is a key suppressor of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human glioblastoma multiforme (GBM) cells. We previously reported that a novel phosphatase and tensin homologue (PTEN)-Akt-atrophin-interacting protein 4 (AIP4) pathway regulates FLIP(S) ubiquitination and stability, although the means by which PTEN and Akt were linked to AIP4 activity were unclear. Here, we report that a second regulator of ubiquitin metabolism, the ubiquitin-specific protease 8 (USP8), is a downstream target of Akt, and that USP8 links Akt to AIP4 and the regulation of FLIP(S) stability and TRAIL resistance. In human GBM xenografts, levels of USP8 correlated inversely with pAkt levels, and genetic or pharmacologic manipulation of Akt regulated USP8 levels in an inverse manner. Overexpression of wild-type USP8, but not catalytically inactive USP8, increased FLIP(S) ubiquitination, decreased FLIP(S) half-life, decreased FLIP(S) steady-state levels, and decreased TRAIL resistance, whereas short interfering RNA (siRNA)-mediated suppression of USP8 levels had the opposite effect. Because high levels of the USP8 deubiquitinase correlated with high levels of FLIP(S) ubiquitination, USP8 seemed to control FLIP(S) ubiquitination through an intermediate target. Consistent with this idea, overexpression of wild-type USP8 decreased the ubiquitination of the FLIP(S) E3 ubiquitin ligase AIP4, an event previously shown to increase AIP4-FLIP(S) interaction, whereas siRNA-mediated suppression of USP8 increased AIP4 ubiquitination. Furthermore, the suppression of FLIP(S) levels by USP8 overexpression was reversed by the introduction of siRNA targeting AIP4. These results show that USP8, a downstream target of Akt, regulates the ability of AIP4 to control FLIP(S) stability and TRAIL sensitivity.
凋亡抑制蛋白 FLIP(S)是一种关键的肿瘤坏死因子相关凋亡诱导配体(TRAIL)诱导的人多形性胶质母细胞瘤(GBM)细胞凋亡的抑制剂。我们之前报道过,一种新的磷酸酶和张力蛋白同系物(PTEN)-Akt-萎缩蛋白相互作用蛋白 4(AIP4)途径调节 FLIP(S)的泛素化和稳定性,尽管 PTEN 和 Akt 与 AIP4 活性的连接方式尚不清楚。在这里,我们报告说,泛素代谢的另一种调节剂,泛素特异性蛋白酶 8(USP8),是 Akt 的下游靶标,USP8 将 Akt 与 AIP4 及其对 FLIP(S)稳定性和 TRAIL 抗性的调节联系起来。在人 GBM 异种移植瘤中,USP8 的水平与 pAkt 水平呈负相关,并且 Akt 的遗传或药理学操作以相反的方式调节 USP8 水平。野生型 USP8 的过表达,但不是无催化活性的 USP8,增加了 FLIP(S)的泛素化,降低了 FLIP(S)的半衰期,降低了 FLIP(S)的稳态水平,并降低了 TRAIL 的耐药性,而 siRNA 介导的 USP8 水平的抑制则产生了相反的效果。由于高 USP8 去泛素酶水平与高 FLIP(S)泛素化水平相关,USP8 似乎通过中间靶标控制 FLIP(S)泛素化。与这一观点一致,野生型 USP8 的过表达降低了 FLIP(S)E3 泛素连接酶 AIP4 的泛素化,先前的研究表明这增加了 AIP4-FLIP(S)相互作用,而 siRNA 介导的 USP8 抑制增加了 AIP4 的泛素化。此外,USP8 过表达对 FLIP(S)水平的抑制作用被针对 AIP4 的 siRNA 的引入所逆转。这些结果表明,Akt 的下游靶标 USP8 调节 AIP4 控制 FLIP(S)稳定性和 TRAIL 敏感性的能力。